Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

6.7%

1 terminated/withdrawn out of 15 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

40%

6 trials in Phase 3/4

Results Transparency

75%

6 of 8 completed trials have results

Key Signals

3 recruiting6 with results

Enrollment Performance

Analytics

Phase 2

7(46.7%)

Phase 3

6(40.0%)

Phase 1

2(13.3%)

15Total

Phase 2(7)

Phase 3(6)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT07553988Phase 2Active Not Recruiting

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

Role: lead

NCT07517575Phase 2Recruiting

Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis

Role: lead

NCT07206043Phase 1Completed

Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers

Role: lead

NCT05190991Phase 2Recruiting

Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

Role: lead

NCT05092776Phase 2Active Not Recruiting

Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine

Role: lead

NCT06440746Phase 2Recruiting

Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

Role: lead

NCT05432960Phase 3Withdrawn

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Role: lead

NCT05673902Phase 3Active Not Recruiting

Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis

Role: lead

NCT04246762Phase 1Completed

Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

Role: lead

NCT03120949Phase 3Completed

Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis

Role: lead

NCT02760407Phase 3Completed

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Role: lead

NCT02760368Phase 3Completed

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Role: lead

NCT02760433Phase 3Completed

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

Role: lead

NCT04692766Phase 2Completed

Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis

Role: lead

NCT04380519Phase 2Completed

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

Role: lead

All 15 trials loaded